Source comparison
MK-677 for Frailty Research: Study Design Comparison
Dose Range 12.5–25 mg daily 25–50 mg daily Frailty research uses lower doses to minimize adverse events while maintaining anabolic effect in older populations Primary Endpoint Gait speed, grip strength, SPPB score Lean mass gain, strength PRs Functional capaci
This comparison does not assign a generated winner or score.
- Dose Range
- 12.5–25 mg daily
- 25–50 mg daily
- Frailty research uses lower doses to minimize adverse events while maintaining anabolic effect in older populations
- Primary Endpoint
- Gait speed, grip strength, SPPB score
- Lean mass gain, strength PRs
- Functional capacity (not absolute size) defines success in clinical frailty settings
- Treatment Duration
- 12–24 months minimum
- 8–16 weeks typical
- Long-term trials are necessary to measure frailty progression. Short cycles miss the endpoint
- Population Age
- 65–85+ years
- 20–50 years
- Older populations show proportionally larger functional improvements at lower absolute lean mass gains
- Monitoring Frequency
- Monthly glucose, edema checks
- Sporadic or self-monitored
- Clinical trials require structured safety monitoring due to comorbidity burden in frail elderly